ASCO
Infinity Pharma $INFI will present one abstarct (available 5/16) at ASCO in June. This will be data from a phase 1b saridegib (IPI-926) trial in combination with FOLFIRINOX in pancreas cancer. Note that a prior phase 2 trial in combination with gemcitabine for pancreatic cancer (based on the phase 1 data presented at ASCO 2011 and ASCO-GU 2012) has since been terminated in January 2012.
Partner updates
INFI licensed a pain drug (FAAH inhibitor) IPI-940 to Purdue Pharma after phase 1. A phase 2 was projected to start in 2011 but I have yet to find any evidence that this has occurred. Purdue is a private company so additional details are sparse. Personal communication with INFI investor relations in February 2012 confirmed that the program had not been terminated and that they "expect" Purdue to initiate phase 2 trials in pain.
Infinity Pharma $INFI will present one abstarct (available 5/16) at ASCO in June. This will be data from a phase 1b saridegib (IPI-926) trial in combination with FOLFIRINOX in pancreas cancer. Note that a prior phase 2 trial in combination with gemcitabine for pancreatic cancer (based on the phase 1 data presented at ASCO 2011 and ASCO-GU 2012) has since been terminated in January 2012.
Partner updates
INFI licensed a pain drug (FAAH inhibitor) IPI-940 to Purdue Pharma after phase 1. A phase 2 was projected to start in 2011 but I have yet to find any evidence that this has occurred. Purdue is a private company so additional details are sparse. Personal communication with INFI investor relations in February 2012 confirmed that the program had not been terminated and that they "expect" Purdue to initiate phase 2 trials in pain.
RSS Feed
